Zealand Pharma Informs That Data Presented on Lyxumia® Support Known Complementary Effects of This Diabetes Medicine in Combination With Basal Insulin
Published: Sep 24, 2013
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that new sub-analysis results from the GetGoal-L Phase III clinical study show that reductions in HbA1c with Lyxumia® (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). Reductions in body weight with Lyxumia®, when added to basal insulin, were also greatest in this group. The new results were presented today in an oral session at the 49th Annual Meeting of the European Association for the Study of Diabetes in Barcelona.
Help employers find you! Check out all the jobs and post your resume.